MyoVision has announced the release of the SERIES-5, an FDA-cleared, class II medical diagnostic system that diagnoses soft tissue injury. It effectively invalidates expert opinion by providing objective evidence of injury proving injury and exposing symptom magnifiers. The device simultaneously measures range of motion and the muscular guarding response during motion, providing a truly objective answer to the age-old question, “Are you really in pain?”

Abnormal muscle activation, known as muscle guarding, is the body’s natural response to pain. By documenting muscle guarding during motion, the SERIES-5 provides doctors, jurors, IMEs and patients with consistent objective outcomes. The SERIES-5 increases sensitivity and specificity of range of motion to a level that improves the accuracy of clinical evaluation. It proves with clinical certainty if a patient is injured and in pain or if they are not.

Unlike static evaluations (e.g. MRI, CT or Endpoint ROM), the test is performed in motion, making it a functional test which elicits the pain response.  Further enhancing the SERIES-5 sensitivity and specificity and what lowers the percentage of false negatives is that the test is performed in all motions (flexion, extension, lateral and rotation).

The SERIES-5 utilizes a 100% WireFree technology suitable for hospital use and takes essentially the same time as traditional ROM. Its proprietary receiver provides sophisticated noise reduction and seamless connectivity to any computer in any clinical environment. It was developed by David Marcarian, MA, a NASA-trained engineer who was recently honored with an appointment as clinical instructor at the University at Buffalo, Jacobs School of Medicine and Medical Sciences, teaching radiology students how to utilize this new technology.

Featured in the AMA’s guidebook, “The Practical Guide to Range of Motion Assessment,” the SERIES-5 is being hailed as the new gold standard in injury evaluation.

About MyoVision
A passion for excellence. A passion for innovation. A passion for quality. These are the driving forces behind the MyoVision success story. Developed under a prestigious NIH Grant, the new SERIES-5 is the result of thousands of hours of R&D and clinical application in the health care arena. MyoVision has been manufacturing medical equipment in the U.S. for the past 30 years. For more information, visit myovision.com or email [email protected]

The post Pain response now measurable with new SERIES-5 MyoVision diagnostic system appeared first on Chiropractic Economics.




By: Chiropractic Economics
Title: Pain response now measurable with new SERIES-5 MyoVision diagnostic system
Sourced From: www.chiroeco.com/pain-response-now-measurable-with-new-series-5-myovision-diagnostic-system/
Published Date: Thu, 11 Mar 2021 21:18:36 +0000